- Home
- ARMP vs IKNA Comparison
ARMP vs IKNA Comparison
Compare ARMP & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- IKNA
- Stock Information
- Founded
- ARMP N/A
- IKNA 2016
- Country
- ARMP United States
- IKNA United States
- Employees
- ARMP N/A
- IKNA N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- IKNA Health Care
- Exchange
- ARMP Nasdaq
- IKNA Nasdaq
- Market Cap
- ARMP 52.1M
- IKNA 61.8M
- IPO Year
- ARMP N/A
- IKNA 2021
- Fundamental
- Price
- ARMP $1.23
- IKNA $1.11
- Analyst Decision
- ARMP Strong Buy
- IKNA Buy
- Analyst Count
- ARMP 1
- IKNA 2
- Target Price
- ARMP $7.00
- IKNA $3.00
- AVG Volume (30 Days)
- ARMP 30.3K
- IKNA 84.2K
- Earning Date
- ARMP 05-06-2025
- IKNA 05-12-2025
- Dividend Yield
- ARMP N/A
- IKNA N/A
- EPS Growth
- ARMP N/A
- IKNA N/A
- EPS
- ARMP N/A
- IKNA N/A
- Revenue
- ARMP $5,174,000.00
- IKNA N/A
- Revenue This Year
- ARMP $8.43
- IKNA N/A
- Revenue Next Year
- ARMP N/A
- IKNA N/A
- P/E Ratio
- ARMP N/A
- IKNA N/A
- Revenue Growth
- ARMP 14.24
- IKNA N/A
- 52 Week Low
- ARMP $0.90
- IKNA $0.97
- 52 Week High
- ARMP $3.45
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- ARMP 39.22
- IKNA 38.47
- Support Level
- ARMP $1.11
- IKNA $1.06
- Resistance Level
- ARMP $1.30
- IKNA $1.25
- Average True Range (ATR)
- ARMP 0.14
- IKNA 0.10
- MACD
- ARMP 0.01
- IKNA 0.00
- Stochastic Oscillator
- ARMP 42.86
- IKNA 39.83
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.